Interactive Learning

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: July 15th, 2012 - July 16th, 2013

Program Description

Historically, multiple myeloma (MM) was a difficult and frustrating disease. Fortunately, during the past decade, significant advances have been made in our understanding of the natural history and pathogenesis of MM and factors that influence outcomes. In addition, novel therapies have been developed that are highly effective, provide disease control, and prolong survival without detrimentally affecting quality of life.

The availability of the novel therapies, including bortezomib, lenalidomide, and thalidomide, along with well-defined prognostic factors, has afforded the development of risk-adapted strategies for managing MM. Within recent years, there have been a great number of clinical trials that have yielded a plethora of data regarding the appropriate timing of certain therapies, optimal combination regimens, incorporation of autologous stem-cell transplant (ASCT) into a management strategy, the place for allogeneic transplant, and controlling adverse events. Recommended guidelines are continually updated. As a result, multiple “acceptable” evidence-based options make providing “real-life” care confusing. This activity will provide attendees with an in-depth understanding of the treatment strategies for MM. 

Learning Objectives

  • Describe recent advances and emerging therapies in the treatment of patients with MM
  • Discuss the impact of evolving strategies with new agents and combination regimens
  • Evaluate the healthcare value proposition associated with emerging therapies and evolving treatment strategies for MM

Target Audience
This activity is developed for physicians, nurses, pharmacists, and managed care professionals who are involved in the care of patients with multiple myeloma.

Physician Accreditation
The Medical Learning Institute, Inc. (MLI) designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Medical Learning Institute, Inc. and Center of Excellence Media, LLC. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1 contact hour.

Registered Pharmacy Designation
Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.  Completion of this activity provides for 1 contact hour (0.1 CEU) of continuing education credit.
The Universal Activity Number for this activity is 0468-9999-12-021-H01-P.

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity for any amount during the past 12 months.

Planners' and Managers' Disclosures
Puthugramam Natrajan, MD, FACOG, CCD disclosed that he is on the Speakers Bureau of Warner Chilcott
Lorrie McSherry, RN, BSN, OCN disclosed that she is on the advisory Board of Onyx
Nancy Nesser, JD, PharmD has nothing to disclose

Faculty Disclosures
Jonathan L. Kaufman, MD discloses that he is a consultant for Celgene and Millennium pharmaceuticals.  He does not intend to discuss non-FDA approved drugs or investigational use of any product/device.

Atheer A. Kaddis, PharmD has nothing to disclose.  He does not intend to discuss non-FDA approved drugs or investigational use of any product/device.

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias toward or promotion for any agent discussed in this program should be inferred.

Related Items
Myelofibrosis and Multiple Myeloma: Strategies for Effective Decision-Making
Martha L. Arellano, MD, Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA, Gary M. Owens, MD
Supplements published on July 31, 2012
Emerging Treatments and Evolving Strategies for the Cost-Effective Management of Myelofibrosis
Gary M. Owens, MD, Alfonso Quintas-Cardama, MD , Atheer A. Kaddis, PharmD
Interactive Learning published on July 15, 2012
Perspectives on Recent Clinical Practice Guideline Updates for the Management of Chemotherapy-Induced Nausea and Vomiting
Atheer A. Kaddis, PharmD , James J. Natale, PharmD, BCOP, Kimberly Noonan, MS, RN, ANP, AOCN, Steven M. Grunberg, MD
Supplements published on June 15, 2012
Payer Perspective ASH 2011 Update: Multiple Myeloma Treatment Trends and Strategies for Value-Based Care
Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA
Supplements published on March 5, 2012
Considerations in Multiple Myeloma Ask the Experts: Newly Diagnosed Patients
Jonathan L. Kaufman, MD , Charise Gleason, MSN, ANP-BC, AOCNP, R. Donald Harvey, PharmD, FCCP, BCPS, BCOP
Supplements published on March 31, 2011
Challenging Cases in Multiple Myeloma: A Dialogue Between Community and Academic Clinicians to Improve Patient Care and Outcomes
Leon Dragon, MD, FACP, Hakan Kaya, MD, Jonathan L. Kaufman, MD , Shoba Kankipati, MD , Noopur Raje, MD, Ari Umutyan, MD
Supplements published on December 3, 2010
Last modified: March 7, 2014